8-K: Cocrystal Pharma Stockholders Affirm Board, Auditor, and New Equity Plan at Annual Meeting

Cocrystal Pharma, Inc. announced that its stockholders approved the election of all six director nominees, ratified Weinberg & Company as its independent auditor, and adopted the 2025 Equity Incentive Plan at its 2025 Annual Meeting.

Summary

• Stockholders elected six individuals to the Board of Directors for a one-year term: Dr. Roger Kornberg (4,386,691 votes For), Dr. Phillip Frost (4,344,444 votes For), Mr. Fred Hassan (4,440,602 votes For), Dr. Anthony Japour (4,368,008 votes For), Mr. Richard C. Pfenniger, Jr. (4,330,382 votes For), and Mr. Steven Rubin (3,954,490 votes For).
• The appointment of Weinberg & Company as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified with 6,166,964 votes For, 452,222 votes Against, and 10,193 Abstentions.
• The 2025 Equity Incentive Plan was approved by stockholders with 3,764,418 votes For, 714,962 votes Against, and 13,797 Abstentions.
• A proposal to adjourn the meeting, if necessary, to solicit further proxies was rendered moot as sufficient votes were obtained for all other proposals.

Sentiment

Score: 7

Explanation: All management-backed proposals passed with significant shareholder support, reflecting stability in corporate governance and strategic direction.

Positives

• All six director nominees were successfully elected, indicating continued shareholder confidence in the current board.
• The appointment of Weinberg & Company as the independent auditor was ratified with strong majority support.
• The 2025 Equity Incentive Plan was approved, providing a mechanism for attracting and retaining talent through equity compensation.

Future Outlook

The approval of the 2025 Equity Incentive Plan suggests a forward-looking approach to talent management and compensation, aligning employee incentives with shareholder interests.

Industry Context

This filing represents a routine corporate governance update, common across publicly traded companies, reflecting the outcomes of their annual stockholder meetings. It does not contain information specific to broader industry trends or competitive dynamics.

Corporate Governance

Stakeholder Impact

• Shareholders: Approved key corporate governance matters, including board composition and an equity incentive plan, which can impact future share dilution and management alignment.
• Employees: The approval of the 2025 Equity Incentive Plan provides a framework for potential equity awards, which can serve as a significant component of compensation and retention.

Next Steps

• The elected directors will hold office until the next annual meeting of stockholders.
• Weinberg & Company will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The 2025 Equity Incentive Plan is now effective and can be utilized for equity compensation.

Key Dates

Recommendation

Keywords

Cocrystal Pharma, COCP, Annual Meeting, Stockholder Vote, Board of Directors, Director Election, Auditor Ratification, Equity Incentive Plan, Corporate Governance, SEC Filing